Sutent 25mg is a prescription drugs which is used under the guidance of medical practioners.
Sutent 25mg is a type of targeted therapy and is a receptor protein-tyrosine kinase inhibitor. It prevents the actions of vascular endothelial growth factor (VEGF) and is an angiogenesis inhibitor.
Sunitinib is a generic form of brand name Sutent 25mg and the drug is a cancer medicine which prevents the development and spread of cancer cells in the body.


Sutent 25mg is used for the treatment in patients with Gastrointestinal stromal tumor.
Sutent 25mg is used for the treatment in patients with Advanced pancreatic neuroendocrine tumor
Sutent 25mg is used for the treatment in patients with Advanced renal cell cancer


Sunitinib belongs to type of targeted therapy drug called a tyrosine kinase inhibitor. It performs by inhibiting signals in cancer cells that make them develop and divide. This may support to blocks the cancer development or slow it down. Sunitinib can also prevents cancer cells from producing new blood vessels. This decrease their supply of oxygen and nutrients, so the tumour shrinks or inhibit growing.

Dosage & Administration

The recommended dosage for following condition as follows :
Gastrointestinal Stromal Tumor :
Dose after disease progression on or intolerance to imatinib mesylate
The recommended dose is 50 mg PO qDay for 4 weeks, followed by 2 weeks drug-free, repeat cycle
Renal Cell Carcinoma :
The recommended dose is 50 mg PO qDay for 4 weeks, followed by 2 weeks drug-free, repeat cycle
Adjuvant treatment of RCC :
• used for the adjuvant therapy of adult patients at high risk of recurrent RCC following nephrectomy
• The recommended dose is 50 mg PO qDay for 4 weeks, followed by 2 weeks drug-free, repeat cycle for a maximum of nine 6-week cycles totally
Pancreatic Neuroendocrine Tumor :
The recommended dose is 37.5 mg PO qDay continuously without a scheduled off-treatment period


peak plasma level of sunitinib is between 6 and 12 hours and the bioavailability of sunitinib has no effect on food.
Bounding of human serum protein was 95 % and 90 % respectively.
Mainly metabolized by cytochrome P450 enzyme, CYP3A4
The drug sunitinib is eliminated primarily through feces 61% and renal excretion is 16% of administrated dose. Sunitinib half-life is 40 – 60 hours
Primary active metabolite half-life was 80 – 110 hours.


Control urine protein; interfere with treatment for 24-hr urine protein ≥3 g; stop for repeat episodes of protein ≥3 g despite dose reductions or nephrotic syndrome
Hypothyroidism occurred; check the baseline thyroid function in patients with hypothyroidism or hyperthyroidism and treat per standard medical practice prior to initiating therapy
Sutent 25mg treatment will causes severe hepatotoxicity involving liver failure; check liver function tests before starting treatment.
Haemorrhagic events involving tumor-related haemorrhage resulted; test the serial complete blood counts and physical examinations
Adrenal haemorrhage occurred in animal studies; check the adrenal function in case of stress such as surgery, trauma or severe infection
Impaired wound healing resulted; temporary interfere with treatment recommended if go through major surgical procedures

Drug Interaction

Sutent 25mg Concomitant use with CYP3A4 inhibitors (ketoconazole0 will increase the sunitinib plasma concentrations.
Sutent 25mg Concomitant use with CYP3A4 inducers (rifampin) will decrease Sunitinib plasma concentration


Advise females of reproductive possible of the probable hazard to a foetus and use of effective contraception.

Side Effects

Common side effects:
Signs of allergic reactions: hives, breathing difficulty, sore throat, skin pain, red or purple skin rash
Liver problem: upper stomach pain, itching, tried feeling, decreased appetite, dark urine, jaundice.
Serious side effects:
Swelling in ankles or feet
Fast heart beats
Sudden dizziness
Shortness of breath
Unusual bruising
Signs of tumor cell breakdown :
muscle cramps, tiredness, decreased urination, slow heart rate.
Thyroid problem :
severe tiredness, depression, rapid heart rate, , feeling nervous, sweating, nausea, vomiting, diarrhea, loss of hair, weight changes, irregular menstrual periods.

Missed Dose

If dose is missed the have the dose immediately before next dose timing reaches or skip the missed dose and continue the regular schedule. Consult doctors regarding missed dose.


Possible of severe side effects in breastfed infants from sunitinib, avoid breast feeding during treatment.


Stored at controlled temperature at 250C Dispense only in its original carton


Patients are contraindicated with Sutent 25mg due to hypersensitivity and renal impairment.

Connect With Us

Prescription Medication Policy

1., a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from
6. At, a Caregiver can order prescription medicines on your behalf.